558 related articles for article (PubMed ID: 33106354)
1. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial.
de Groot P; Nikolic T; Pellegrini S; Sordi V; Imangaliyev S; Rampanelli E; Hanssen N; Attaye I; Bakker G; Duinkerken G; Joosten A; Prodan A; Levin E; Levels H; Potter van Loon B; van Bon A; Brouwer C; van Dam S; Simsek S; van Raalte D; Stam F; Gerdes V; Hoogma R; Diekman M; Gerding M; Rustemeijer C; de Bakker B; Hoekstra J; Zwinderman A; Bergman J; Holleman F; Piemonti L; De Vos W; Roep B; Nieuwdorp M
Gut; 2021 Jan; 70(1):92-105. PubMed ID: 33106354
[TBL] [Abstract][Full Text] [Related]
2. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time.
de Groot P; Scheithauer T; Bakker GJ; Prodan A; Levin E; Khan MT; Herrema H; Ackermans M; Serlie MJM; de Brauw M; Levels JHM; Sales A; Gerdes VE; Ståhlman M; Schimmel AWM; Dallinga-Thie G; Bergman JJ; Holleman F; Hoekstra JBL; Groen A; Bäckhed F; Nieuwdorp M
Gut; 2020 Mar; 69(3):502-512. PubMed ID: 31147381
[TBL] [Abstract][Full Text] [Related]
3. Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome.
Holster S; Hooiveld GJ; Repsilber D; Vos WM; Brummer RJ; König J
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31597320
[TBL] [Abstract][Full Text] [Related]
4. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition.
Kootte RS; Levin E; Salojärvi J; Smits LP; Hartstra AV; Udayappan SD; Hermes G; Bouter KE; Koopen AM; Holst JJ; Knop FK; Blaak EE; Zhao J; Smidt H; Harms AC; Hankemeijer T; Bergman JJGHM; Romijn HA; Schaap FG; Olde Damink SWM; Ackermans MT; Dallinga-Thie GM; Zoetendal E; de Vos WM; Serlie MJ; Stroes ESG; Groen AK; Nieuwdorp M
Cell Metab; 2017 Oct; 26(4):611-619.e6. PubMed ID: 28978426
[TBL] [Abstract][Full Text] [Related]
5. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM
Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
Lahtinen P; Jalanka J; Hartikainen A; Mattila E; Hillilä M; Punkkinen J; Koskenpato J; Anttila VJ; Tillonen J; Satokari R; Arkkila P
Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
[TBL] [Abstract][Full Text] [Related]
7. Effects of fecal microbiota transplant on DNA methylation in subjects with metabolic syndrome.
van der Vossen EWJ; Bastos D; Stols-Gonçalves D; de Goffau MC; Davids M; Pereira JPB; Li Yim AYF; Henneman P; Netea MG; de Vos WM; de Jonge W; Groen AK; Nieuwdorp M; Levin E
Gut Microbes; 2021; 13(1):1993513. PubMed ID: 34747338
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study.
Holster S; Lindqvist CM; Repsilber D; Salonen A; de Vos WM; König J; Brummer RJ
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00034. PubMed ID: 31009405
[TBL] [Abstract][Full Text] [Related]
9. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial.
Ng SC; Xu Z; Mak JWY; Yang K; Liu Q; Zuo T; Tang W; Lau L; Lui RN; Wong SH; Tse YK; Li AYL; Cheung K; Ching JYL; Wong VWS; Kong APS; Ma RCW; Chow EYK; Wong SKH; Ho ICH; Chan PKS; Chan FKL
Gut; 2022 Apr; 71(4):716-723. PubMed ID: 33785557
[TBL] [Abstract][Full Text] [Related]
10. Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota.
Pellegrini S; Sordi V; Bolla AM; Saita D; Ferrarese R; Canducci F; Clementi M; Invernizzi F; Mariani A; Bonfanti R; Barera G; Testoni PA; Doglioni C; Bosi E; Piemonti L
J Clin Endocrinol Metab; 2017 May; 102(5):1468-1477. PubMed ID: 28324102
[TBL] [Abstract][Full Text] [Related]
11. Faecal microbiota transplantation in endocrine diseases and obesity.
Fuhri Snethlage CM; Nieuwdorp M; Hanssen NMJ
Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101483. PubMed ID: 33414033
[TBL] [Abstract][Full Text] [Related]
12. An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
Buchanan K; Mehdi AM; Hughes I; Cotterill A; Le Cao KA; Thomas R; Harris M
Pediatr Diabetes; 2019 Mar; 20(2):166-171. PubMed ID: 30556344
[TBL] [Abstract][Full Text] [Related]
13. Correlations between microbiota and metabolites after faecal microbiota transfer in irritable bowel syndrome.
Holster S; Repsilber D; Geng D; Hyötyläinen T; Salonen A; Lindqvist CM; Rajan SK; de Vos WM; Brummer RJ; König J
Benef Microbes; 2021 Feb; 12(1):17-30. PubMed ID: 33350360
[TBL] [Abstract][Full Text] [Related]
14. Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach.
Stols-Gonçalves D; Mak AL; Madsen MS; van der Vossen EWJ; Bruinstroop E; Henneman P; Mol F; Scheithauer TPM; Smits L; Witjes J; Meijnikman AS; Verheij J; Nieuwdorp M; Holleboom AG; Levin E
Gut Microbes; 2023 Dec; 15(1):2223330. PubMed ID: 37317027
[TBL] [Abstract][Full Text] [Related]
15. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.
Craven L; Rahman A; Nair Parvathy S; Beaton M; Silverman J; Qumosani K; Hramiak I; Hegele R; Joy T; Meddings J; Urquhart B; Harvie R; McKenzie C; Summers K; Reid G; Burton JP; Silverman M
Am J Gastroenterol; 2020 Jul; 115(7):1055-1065. PubMed ID: 32618656
[TBL] [Abstract][Full Text] [Related]
16. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.
Staley C; Kelly CR; Brandt LJ; Khoruts A; Sadowsky MJ
mBio; 2016 Dec; 7(6):. PubMed ID: 27999162
[TBL] [Abstract][Full Text] [Related]
17. Protocol for a double-blinded randomised controlled trial to assess the effect of faecal microbiota transplantations on thyroid reserve in patients with subclinical autoimmune hypothyroidism in the Netherlands: the IMITHOT trial.
Fenneman AC; Rampanelli E; van der Spek AH; Fliers E; Nieuwdorp M
BMJ Open; 2023 Sep; 13(9):e073971. PubMed ID: 37709342
[TBL] [Abstract][Full Text] [Related]
18. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora.
Wei Y; Gong J; Zhu W; Tian H; Ding C; Gu L; Li N; Li J
BMC Microbiol; 2016 Nov; 16(1):255. PubMed ID: 27809778
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota-testis axis: FMT improves systemic and testicular micro-environment to increase semen quality in type 1 diabetes.
Hao Y; Feng Y; Yan X; Chen L; Zhong R; Tang X; Shen W; Sun Q; Sun Z; Ren Y; Zhang H; Zhao Y
Mol Med; 2022 Apr; 28(1):45. PubMed ID: 35468731
[TBL] [Abstract][Full Text] [Related]
20. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets.
Wang H; Lu Y; Yan Y; Tian S; Zheng D; Leng D; Wang C; Jiao J; Wang Z; Bai Y
Front Cell Infect Microbiol; 2019; 9():455. PubMed ID: 32010641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
